Tag:

antibodies

Latest Headlines

Latest Headlines

Antibody 'cocktail' looks promising against deadly Marburg virus

In a recent study, scientists at The Scripps Research Institute have characterized new antibodies that protect against the ebolavirus' sinister relative--the Marburg virus.

Kite taps Adimab to lend a hand in CAR-T R&D

Kite Pharma, at work on therapies that use the immune system to fight cancer, paired up with Adimab to expand its R&D efforts.

GlaxoSmithKline's new asthma drug gets a split vote from FDA advisers

A group of FDA advisers backed GlaxoSmithKline's latest asthma treatment for use in adults but balked at recommending it for adolescents, setting the stage for a likely approval in the fall.

Ablynx adds Genzyme to roster of big-name collaborators

Ablynx has entered into a collaboration with Sanofi's Genzyme to investigate the use of its single-domain antibodies against a target involved with multiple sclerosis. The deal gives Genzyme the exclusive right to test the antibodies in models relevant to multiple sclerosis.

Third Rock's Jounce bags $56M to hit the gas in immuno-oncology

While Merck and Bristol-Myers Squibb grab global headlines with treatments designed to make it harder for cancer to hide from the immune system, Cambridge, MA's Jounce Therapeutics is coming at it from the other end, crafting a therapy that revs up the body's natural defenses to attack tumors. And the promise of that idea helped the biotech rope in a massive $56 million B round, cash that will help get its top prospect into clinical trials.

Biogen gives Roche 'renewed confidence' in its own failed Alzheimer's drugs

Biogen turned heads around the industry last month with early data in which its plaque-destroying Alzheimer's treatment had a significant effect on patients' cognition, bucking a vexing trend for such antibodies. Among those paying close attention was Roche, which is now re-examining a pair of once-failed treatments.

Following a setback, Pfizer gets a win in Phase III cancer drug study

Two years after going down in flames in a Phase III study for CD22-positive non-Hodgkin's lymphoma, Pfizer has helped resurrect hopes for top drug prospect inotuzumab ozogamicin, saying the drug hit its first primary endpoint for spurring hematologic remission in patients with CD22-positive acute lymphoblastic leukemia.

White House calls for advancing rapid diagnostics to combat drug-resistant bacteria

The diagnostics industry will play a significant role in the Obama administration's just-released national action plan to combat the rise of antibiotic-resistant bacteria, such as CRE, which was implicated in the recent death of at least two patients in Los Angeles and many illnesses nationwide.

Academic team assembles a 'homegrown' immunotoxin for blood cancers

An oncologist at the University of Minnesota has devised a "homegrown" bispecific antibody that binds to both CD19 and CD22, proteins found on the surface of B-cell blood cancers, and drops a toxic payload on the targeted cells. In a Phase I trial with 10 evaluable patients with treatment resistant pre-B acute lymphoblastic leukemia, chronic lymphocytic leukemia, or non-Hodgkin lymphoma, two had a durable response, with one complete remission. And that is setting the stage for a mid-stage study of a drug that has been pushed this far largely with private donations.

Incyte, Agenus partner on immuno-oncology targets in $410M deal

Incyte is jumping aboard Agenus' antibody discovery platform, signing up to partner on new immuno-oncology drugs with $60 million in cash and promises of up to $350 million in milestones. And the deal news quickly drove up Agenus' shares by more than 30% in premarket trading.